Long term remissions with combined modality therapy for advanced Hodgkin's disease
- 1 June 1976
- Vol. 37 (6), 2826-2833
- https://doi.org/10.1002/1097-0142(197606)37:6<2826::aid-cncr2820370638>3.0.co;2-f
Abstract
A new treatment program for advanced Hodgkin's disease employing five-drug combination chemotherapy and low dose radiation to the sites of bulk disease (nodal or parenchymal) was designed in 1969. Eighty patients have now been treated, 60 of whom have achieved a complete remission. More significantly, only 5 of the 60 complete responders have relapsed with followup from 1–6 years. The cumulative survival at 5 years of patients entering complete remission is 92%. For those patients not sustaining a complete remission, it is 19% at 2 years. This program has resulted in substantially lower relapse rates than previously reported by other investigators, probably because of the administration of radiotherapy in the manner described. Hopefully, a significant number of these patients may be cured of their disease.This publication has 13 references indexed in Scilit:
- The management of Hodgkin's diseaseCancer, 1975
- Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPPCancer, 1975
- Hodgkin's disease and acute leukemiaAmerican Journal Of Medicine, 1975
- Multiple Chemotherapeutic Agents for Hodgkin DiseasePublished by American Medical Association (AMA) ,1973
- Combination Chemotherapy in Advanced Hodgkin's DiseaseAnnals of Internal Medicine, 1973
- MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSIONThe Lancet, 1973
- Low Dose Radiation Therapy and Combination Chemotherapy in the Treatment of Advanced Hodgkin's DiseaseRadiology, 1973
- Combined ChemotherapyArchives of Internal Medicine, 1973
- Combination Chemotherapy-Radiotherapy for Stage III Hodgkin's DiseaseArchives of Internal Medicine, 1973
- Nonlymphomatous Malignant Tumors Complicating Hodgkin's DiseaseNew England Journal of Medicine, 1972